Search
TScan Therapeutics Inc
TCRXAdd to Watchlist
0.920USD
+0.020+2.23%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
60.12MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of TScan Therapeutics Inc is 7.71, ranking 276 out of 389 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 12.00 and a low of 4.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
6.000
Target Price
+566.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
TScan Therapeutics Inc
TCRX
7
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is TScan Therapeutics Inc's expected revenue for the next quarter?
TScan Therapeutics Inc's expected revenue is 1.67M.
What is TScan Therapeutics Inc's price target?
Analysts forecast that TScan Therapeutics Inc's price target is USD 6.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 4.00.
How have TScan Therapeutics IncTCRX's recent earnings per share performed?
The market expectation was USD -0.22, while TScan Therapeutics IncTCRX's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for TScan Therapeutics Inc?
Based on the ratings of TScan Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
